The global wellness industry is a 6.8-trillion-dollar business — more than four times the size of global pharma — and it runs on supplements. But how much of it actually has evidence behind it?
In Episode 14 of Overheard in the Emergency Room, Dr Adrian Cois — a board-certified Emergency Physician — walks through the published systematic reviews and meta-analyses for the nine most common supplements of 2026. Which ones have genuine evidence? Which ones are selling you a story? And how should you make decisions in a regulatory environment where, under DSHEA, supplements do not have to be proven safe or effective before they hit the shelf?
The episode is anchored by two clinical stories: a coworker asking whether any supplement will stop her from getting sick, and an older man on Social Security spending his limited income on a herbal product while eating free meals at a senior centre.
In between, Dr Cois breaks down creatine, vitamin D, omega-3, magnesium, and multivitamins — the five with reasonable evidence — and then takes apart NMN, berberine, collagen, and "detox" supplements — four with very thin evidence and very large marketing budgets.
The episode also takes on the February 2026 FDA peptide reclassification, explains why BPC-157's evidence base is 35 rat studies and one uncontrolled case series, and closes with a blinded randomised-trial comparison between the Pfizer-BioNTech mRNA COVID vaccine trial and the retatrutide phase 2 obesity trial — revealing why influencers who dismissed the first while promoting the second are holding incoherent evidentiary standards.
• Supplements are Tier 2 by definition. They cannotsubstitute for diet, movement, sleep, stress management, and a primary carephysician.
• Five supplements with reasonable evidence in specificpopulations: creatine (resistance training), vitamin D (deficiency, older adults, prediabetes, pregnancy), omega-3 (specific cardiovascular contexts), magnesium (blood pressure, migraines), multivitamins (older adults with imperfect diets).
• Four with large marketing and small evidence: NMN, berberine (outside metabolic syndrome), collagen, and "detox" protocols.
• The BPC-157 evidence base is 35 preclinical animal studies and one uncontrolled case series in 12 humans. Reclassification by the FDA in 2026 restored access; it did not validate evidence.
• The three-question cabinet audit: Is there a medical reason? Can I name the evidence? What could this money do elsewhere?
Note: Final timestamps to be filled in after recording. Use the YouTube chapter block above as the master, then synchronise to Spotify.
Companion blog post with full references, evidence tables, and clinician-facing notes at drcois.com.
Educational content only. Not medical advice. Always consult your own physician before starting, stopping, or modifying any supplement or medication regimen.